Published in Blood Coagul Fibrinolysis on March 01, 1998
Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol (2012) 0.99
Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost (2015) 0.90
Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther (2013) 0.83
Platelets as delivery systems for disease treatments. Adv Drug Deliv Rev (2010) 0.81
Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4. Haemophilia (2014) 0.81
Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report. Blood Transfus (2016) 0.75
Difficulties in the treatment of an Infant with Hemophilia B. Turk Pediatri Ars (2016) 0.75
Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag (2006) 0.75
Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center. Blood Res (2016) 0.75
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol (1999) 1.88
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Automated dithionite test for rapid, inexpensive detection of hemoglobin S and non-S sickling hemoglobinopathies. Clin Chem (1971) 1.24
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia (2009) 1.19
Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med (1980) 1.16
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia (1999) 1.08
Dithionite tube test--a rapid, inexpensive technique for the detection of hemoglobin S and non-S sickling hemoglobin. Clin Chem (1971) 1.08
Idiopathic thrombocytopenic purpura in childhood. J Pediatr (1966) 1.07
B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia (2005) 1.07
Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group. N Engl J Med (1993) 1.02
Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group. BMJ (1992) 0.98
Oral urea and the prophylactic treatment of sickle cell disease--a preliminary report. Am J Med Sci (1971) 0.98
Idiopathic thrombocytopenic purpura in children. Semin Thromb Hemost (1977) 0.97
Anti-s hemolytic disease: a case report. Transfusion (1967) 0.97
Neurological complications of sickle cell anemia. Am J Pediatr Hematol Oncol (1982) 0.96
The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med (1989) 0.94
DDAVP: does the drug have a direct effect on the vessel wall? Thromb Res (1983) 0.94
The incidence of development of irregular red cell antibodies in patients with sickle cell anemia. Transfusion (1986) 0.92
Sickle cell crisis terminated by intravenous urea in sugar solutions--a preliminary report. Am J Med Sci (1971) 0.91
Idiopathic thrombocytopenic purpura in children. The case for management without corticosteroids. Am J Pediatr Hematol Oncol (1984) 0.90
A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol (1976) 0.89
Intravenous gamma globulin treatment for chronic idiopathic thrombocytopenic purpura in children. Am J Med (1984) 0.89
Congenital disorders affecting platelets. Semin Thromb Hemost (1977) 0.89
The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia (2003) 0.86
Open heart surgery in a hemophiliac patient. Hematologic management. Am J Dis Child (1974) 0.85
Preoperative exchange transfusion in sickle cell anemia. J Pediatr Surg (1981) 0.85
Hemophilia A in chromosomal female subjects. J Pediatr (1969) 0.85
Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee. Transfusion (1993) 0.84
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol (1996) 0.84
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica (2000) 0.83
The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies. Blood (1968) 0.83
Structural physiology of the human spleen. Am J Pediatr Hematol Oncol (1979) 0.83
DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr (1983) 0.83
Childhood idiopathic thrombocytopenic purpura. Am J Dis Child (1977) 0.83
Erythropoiesis in sickle cell anaemia during acute infection and crisis. Scand J Haematol (1979) 0.82
Hematological parameters and marrow in vitro colony forming cells in acute lymphoblastic leukemia after cessation of treatment. Nihon Ketsueki Gakkai Zasshi (1980) 0.82
Phenotypic change of acute monocytic leukemia to acute lymphoblastic leukemia on therapy. Am J Pediatr Hematol Oncol (1983) 0.82
Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood (1983) 0.82
Desmopressin and thrombosis. Lancet (1989) 0.81
Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost (1996) 0.81
Platelet-vessel-wall interactions: experiences with von Willebrand platelets. Ann N Y Acad Sci (1981) 0.81
Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia (2000) 0.81
Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura. Am J Hematol (1995) 0.80
HIV and hemophilia. J Thromb Haemost (2007) 0.80
Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients. Haemophilia (2009) 0.80
Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol (1997) 0.80
Arteriovenous shunts in the human spleen. Am J Hematol (1976) 0.79
The human spleen as revealed by scanning electron microscopy. Am J Hematol (1976) 0.79
Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia (2000) 0.79
Severe factor VIII and factor IX deficiency in females. Am J Med (1978) 0.79
Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group. Vox Sang (1990) 0.78
Acute idiopathic thrombocytopenic purpura--management in childhood. Blood (1997) 0.78
Sickledex test for hemoglobin S. A critique. JAMA (1971) 0.78
Familial warfarin resistance in a black child. Am J Pediatr Hematol Oncol (1986) 0.77
The detection of sickle cell hemoglobin in large human populations by an automated technique. Mil Med (1972) 0.77
The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia (2005) 0.76
Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol (1990) 0.76
Macroglobulinemia in a child with acute leukemia. Blood (1974) 0.75
Passive antibody to hepatitis A virus in US haemophiliacs. Lancet (1993) 0.75
Congenital thrombocytopenias. Curr Opin Hematol (1995) 0.75
Lack of inhibitor to monoclonal-antibody purified factor VIII concentrate. Lancet (1990) 0.75
Immunoglobulins in idiopathic thrombocytopenic purpura in childhood. Acta Haematol (1976) 0.75
Essential thrombocythemia in a child: platelet ultrastructure and function. Am J Hematol (1980) 0.75
Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia (1999) 0.75
Intravenous gammaglobulin (Gaminume) for treatment of chronic idiopathic thrombocytopenic purpura (ITP): a two-year follow-up. Am J Hematol (1986) 0.75
Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Thromb Haemost (1995) 0.75
Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Trans Assoc Am Physicians (1980) 0.75
Antibody nature of an AHG (factor 8) inhibitor. J Pediatr (1968) 0.75
Factor VIII concentrates: matching what you see with what you get. JAMA (1985) 0.75
Festschrift in homor of Wolf W. Zuelzer, M.D. Am J Hematol (1976) 0.75
Long-term survivors of acute lymphoblastic leukemia--risk of relapse after cessation of therapy. Med Pediatr Oncol (1981) 0.75
Evaluation of oral urea in the management of sickle cell anemia. Adv Exp Med Biol (1972) 0.75
Viral safety and clotting factor concentrates. Thromb Haemost (1994) 0.75
Infections in leukemic children: a prospective analysis. J Pediatr (1980) 0.75
The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. JAMA (1989) 0.75
Controlled clinical trials with prothrombin complex concentrates. Prog Clin Biol Res (1984) 0.75
Repetitive low-dose radiation therapy for acute stem-cell leukemia. Int J Radiat Oncol Biol Phys (1977) 0.75
IMFRA (intermittent intrathecal methotrexate and fractional radiation) plus chemotherapy in childhood leukemia. Am J Hematol (1976) 0.75
Bone changes in sickle cell disease. Paleopathol Newsl (1975) 0.75
The effect of 5-hydroxytryptamine and epinephrine on newborn platelets. Eur J Pediatr (1978) 0.75
Retrovir therapy in hemophilic children with symptomatic human immunodeficiency virus infection: efficacy and toxicity. Am J Pediatr Hematol Oncol (1990) 0.75
Factor IX inhibitors and anaphylaxis in hemophilia B. Haemophilia (1997) 0.75
The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors. Scand J Haematol Suppl (1984) 0.75
Assessment of response to treatment and design of clinical trials. Prog Clin Biol Res (1984) 0.75
North American study of factor VIII concentrate potency. Scand J Haematol Suppl (1984) 0.75
Absence of inhibitory cells from patients with aplastic anemia or transient erythroblastopenia of childhood on the in vitro growth of erythroid colonies. Nihon Ketsueki Gakkai Zasshi (1980) 0.75
Myocardial necrosis after therapy with prothrombin-complex concentrate. N Engl J Med (1984) 0.75
The problem of therapeutic equivalence with paired qualitative data: an example from a clinical trial using haemophiliacs with an inhibitor to factor VIII. Stat Med (1991) 0.75
Panel discussion on the treatment of patients with factor VIII inhibitors. Prog Clin Biol Res (1984) 0.75
Hemophilia: continued challenges but reason for optimism on many fronts. Transfusion (1993) 0.75
Acute lymphoid leukemia. Pediatr Ann (1978) 0.75